

#16  
AP

Attorney Docket No.: 4318.224-US

**BEST AVAILABLE COPY**

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Bisgaard-Frantzen et al.

Confirmation No: 7527

Serial No.: 09/902,188

Group Art Unit: 1751

Filed: July 10, 2001

Examiner: Prouty

For: Amylase Variants

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
Washington, DC 20231

Sir:


This paper is filed in response to the Office Action mailed March 25, 2003 that made a restriction requirement. Applicants were requested to elect one of two designated groups.

In response to this requirement, Applicants hereby elect the invention of Group I, Claims 68-77, 86-95, 104-113 and 122-131, drawn to alpha-amylase mutants and compositions thereof. Applicants hereby reserve the right to file continuing applications directed to the nonelected subject matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: April 23, 2003

  
\_\_\_\_\_  
Jason I. Garbell, Reg. No. 44,116  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097

**BEST AVAILABLE COPY**



## FAX COVER SHEET

**No. of pages incl. this: 3**

**Telefax no.: (703)308-4242**

**To: Examiner: Prouty**

**From: Jason Garbell**

**Date: April 24, 2003**

**Message:**

**OFFICIAL**

**FAX RECEIVED**

**APR 25 2003**

**GROUP 1600**

---

**Response to Restriction Requirement**

---

---

---

---

---

---

---

**The information contained in this facsimile message is legally privileged and confidential information intended solely for the use of the persons or entities named below. If you are not such persons or entities, you are hereby notified that any distribution, dissemination or reproduction of this facsimile message is strictly prohibited. If you have received this message in error, please immediately call us collect at the above number.**

---

**Novozymes  
North America, Inc.  
Patents-US**

**500 Fifth Avenue,  
Suite 1600  
New York, NY 10110**

**Telephone:  
(212) 840-0097, ext. 15  
Telefax:  
(212) 840-0221**

**email:  
JGar@novozymes.com  
internet:  
www.novozymes.com**

BEST AVAILABLE COPY

Attorney Docket No.: 4318.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgaard-Frantzen et al.

Confirmation No: 7527

Serial No: 09/902,188

Group Art Unit: ~~1754~~ 16052

Filed: July 10, 2001

Examiner: Prouty

For: Amylase Variants

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents  
Washington, DC 20231

Sir:


I hereby certify that the attached correspondence comprising:

1. Response to Restriction Requirement

was sent to the United States Patent Office by telefax to the attention of Examiner Prouty, fax number 703-308-4242.

Respectfully submitted,

Date: April 24, 2003

  
Julie Tabarovsky  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097